Skip to main content
. 2015 Jan 27;2(1):85–96. doi: 10.1007/s40744-015-0008-9

Fig. 1.

Fig. 1

Reported reasons for discontinuation of prior DMARDs in biologic-naive patients initiating a Bio MT and b Bio CMB. Bio CMB biologic in combination with a conventional DMARD, Bio MT biologic monotherapy, DMARD disease-modifying antirheumatic drug, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, SSZ sulfasalazine